Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ViewRay, Inc.VRAY · Entity 111118 | Director | July 19, 2023 | July 21, 2023 |
| Whitehawk Therapeutics, Inc.WHWK · Entity 6074 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ViewRay, Inc.
Report date July 19, 2023 · Filed July 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 99,047 |
Ending reported balance
After 2023-07-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-07-19 · Sale · Disposed 158,397 · Balance 740,080 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.068 to $0.070, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range stated. Row 2 · 2023-07-19 · Sale · Disposed 641,033 · Balance 99,047 F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.069 to $0.070, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range stated. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2023-07-19 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2023-07-19 · Sale · Disposed 1,545,600 · Balance 0 F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.069 to $0.075, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range stated. F4: Shares held by KVP Capital, L.P., an entity controlled by Mr. Castelein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.068 to $0.070, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range stated.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.069 to $0.070, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range stated.
F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.069 to $0.075, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range stated.
F4: Shares held by KVP Capital, L.P., an entity controlled by Mr. Castelein.
Whitehawk Therapeutics, Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2036-06-12 | Direct | 38,040 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 38,040 · Balance 38,040 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Tourmaline Bio, Inc.
Report date October 28, 2025 · Filed October 28, 2025
Section 16 reporting ended · disclosed 2025-10-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 1
1 source rowRow 1 · 2025-10-28 · Other · Disposed 515,997 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F2: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share. |
| Common StockSEC Table I · non-derivative | IndirectBy KVP Capital, LP | 0 |
Reported balance
After 2025-10-28 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-10-28 · Other · Disposed 431,939 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F2: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share. F3: These shares are held by KVP. The Reporting Person is the Managing Member of KVP Capital GP, LLC, the General Partner of KVP and, as such, has sole voting and investment power with respect to the shares held by KVP. The Reporting Person disclaims beneficial ownership of the shares held by KVP except to the extent of his pecuniary interest therein and this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.46 | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-10-28 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F4: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.91 | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-28 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F4: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.73 | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-10-28 · Disposition to issuer · Disposed 16,800 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F4: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration").
F2: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share.
F3: These shares are held by KVP. The Reporting Person is the Managing Member of KVP Capital GP, LLC, the General Partner of KVP and, as such, has sole voting and investment power with respect to the shares held by KVP. The Reporting Person disclaims beneficial ownership of the shares held by KVP except to the extent of his pecuniary interest therein and this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2018 Filed Sep 27, 2018 01:40 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | OtherCommon Stock | 268,987 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-025393 · doc4.xml · nonDerivative · entry 1 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,907 F1 · kind: These shares were received pursuant to a distribution made by Kearny Venture Associates III, LLC in connection with the entity's liquidation. F1 · price: These shares were received pursuant to a distribution made by Kearny Venture Associates III, LLC in connection with the entity's liquidation. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 22:54 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantWarrants (Right to Buy) · Derivative | 11,092 | $0.13 Strike: $3.17 | $1,386.50 |
DisclosureSEC source: 0000899243-18-023266 · doc4.xml · derivative · entry 2 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,092 Underlying: Common Stock · 11,092 shares Expires 2024-01-18 F1 · security: These warrants were received pursuant to a distribution made by Revelation Kearny, LLC and Kearny Venture Associates III, LLC in connection with the liquidation of Revelation Kearny, LLC. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 22:54 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantWarrants (Right to Buy) · Derivative | 28,636 | $0.13 Strike: $2.95 | $3,579.50 |
DisclosureSEC source: 0000899243-18-023266 · doc4.xml · derivative · entry 1 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,636 Underlying: Common Stock · 28,636 shares Expires 2023-08-22 F1 · security: These warrants were received pursuant to a distribution made by Revelation Kearny, LLC and Kearny Venture Associates III, LLC in connection with the liquidation of Revelation Kearny, LLC. Read SEC document |
| August 17, 2018 Filed Aug 20, 2018 20:31 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 510,929 | $9.98 | $5,099,071.42 |
DisclosureSEC source: 0000899243-18-022808 · doc4.xml · nonDerivative · entry 1 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 677,898 F1 · shares: These shares were received pursuant to a distribution made by Revelation Kearny, LLC in connection with the entity's liquidation. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 21:01 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 3,134 | $8.18 | $25,636.12 |
DisclosureSEC source: 0000950103-18-009418 · dp94311_4-castelein.xml · nonDerivative · entry 1 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,969 F1 · price: These shares were issued to the reporting person pursuant to ViewRay, Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $25,639. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:49 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 4,002 | $7.12 | $28,494.24 |
DisclosureSEC source: 0000950103-18-008372 · dp93190_4-castelein.xml · nonDerivative · entry 1 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,835 F1 · shares: 1/6th of these shares shall vest and become exercisable on the last day of each calendar month beginning on July 31, 2018, such that 100% of the shares will be vested on December 31, 2018, subject to the Reporting Person remaining a service provider through each such vesting date. F2 · price: These shares were issued to the reporting person pursuant to ViewRay, Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $28,500. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 22:01 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | GrantStock Option (Right to Buy) · Derivative | 21,400 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017747 · doc4.xml · derivative · entry 1 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,400 Underlying: Common Stock · 21,400 shares Expires 2028-06-20 F1 · derivative.exercise_date: Options shall vest annually on the earlier of the one year anniversary of the Grant Date or the Company's next annual meeting, subject to director's continued service on the Board at such time. Read SEC document |
| December 22, 2017 Filed Feb 14, 2018 22:54 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | OtherCommon Stock | 10,920 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-003902 · doc5.xml · nonDerivative · entry 2 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,920 F3 · ownership.nature: Consists of 10,920 shares of Common Stock distributed to Caley Castelein pursuant to the liquidation of the TWHVP entities. Read SEC document |
| December 22, 2017 Filed Feb 14, 2018 22:54 UTC | Whitehawk Therapeutics, Inc. ARPO · Entity 6074 | OtherCommon Stock | 7,882 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-003902 · doc5.xml · nonDerivative · entry 1 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,603,526 F1 · ownership.nature: Consists of (i) 1,571,475 shares of Common Stock owned directly by Kearny Venture Partners, L.P., or KVP, and (ii) 32,051 shares of Common Stock owned directly by Kearny Venture Partners Entrepreneurs Fund, L.P., or KVPE. The general partner of both KVP and KVPE is Kearny Venture Associates, L.L.C., or KVA. KVA has the sole voting and investment control over the shares owned by KVP and KVPE. The Managing Members of KVA share in the voting and investment control over such shares controlled by KVA. The Managing Members of KVA are Caley Castelein, Richard Spalding and James Shapiro. None of the Managing Members of KVA has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. On December 22, 2017, Revelation TWHVP, LLC and TWHPV SPV, LLC, or the TWHVP entities, F2 · ownership.nature: (Continued from footnote 1) were liquidated and their shares distributed on a pro rata basis to their members. Prior to this liquidation, Kearny Venture Associates II, LLC, or KVA II, was the Managing Member of the TWHVP entities. The Managing Members of KVA II were Caley Castelein, Andrew Jensen and Anupam Dalal. None of the Managing Members of KVA II had individual voting or investment power with respect to such shares and each disclaims past beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| November 15, 2017 Filed Apr 25, 2018 21:03 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantStock Option (right to buy) · Derivative | 45,633 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0000950103-18-005159 · dp89951_4-castelein.xml · derivative · entry 3 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,633 Underlying: Common Stock · 45,633 shares Expires 2027-11-15 F5 · derivative.exercise_date: 27,174 of the shares subject to the option were fully vested on November 15, 2017. 1/12 of the remaining 18,459 shares subject to the option vested and became exercisable on each monthly anniversary measured from June 19, 2017, such that 100% of the shares subject to the option will fully vest on June 19, 2018. Read SEC document |
| November 15, 2017 Filed Apr 25, 2018 21:03 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 8,104 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-18-005159 · dp89951_4-castelein.xml · nonDerivative · entry 1 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,833 F1 · shares: The reported securities are fully vested RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon the earlier of (i) the Reporting Person's termination of service from the Issuer's board of directors or (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan. F2 · balance_after: Includes 29,729 RSUs. Read SEC document |
| October 25, 2017 Filed Nov 10, 2017 00:05 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 130,600 | $6.44 | $841,064.00 |
DisclosureSEC source: 0000899243-17-025869 · doc4.xml · nonDerivative · entry 1 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 282,329 F1 · ownership.nature: By KVP Capital, L.P., an entity controlled by Mr. Castelein. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:58 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 130,104 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-014074 · doc4.xml · nonDerivative · entry 1 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,729 F1 · shares: Represents shares distributed to the Reporting Person by a related fund as part of a pro rata distribution for no consideration. Read SEC document |
| March 15, 2017 Filed Mar 18, 2017 00:42 UTC | Whitehawk Therapeutics, Inc. NONE · Entity 6074 | PurchaseCommon Stock | 400,000 | $5.00 | $2,000,000.00 |
DisclosureSEC source: 0000899243-17-008162 · doc4.xml · nonDerivative · entry 1 Castelein Caley · CIK 0001355758 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,611,408 F1 · ownership.nature: Consists of (i) 392,005 shares of Common Stock owned directly by Kearny Venture Partners, L.P., or KVP, and (ii) 7,995 shares of Common Stock owned directly by Kearny Venture Partners Entrepreneurs Fund, L.P., or KVPE. The general partner of both KVP and KVPE is Kearny Venture Associates, L.L.C., or KVA. KVA has the sole voting and investment control over the shares owned by KVP and KVPE, and the Managing Members of KVA share in the voting and investment control over such shares controlled by KVA. The Managing Members of KVA are Caley Castelein, Richard Spalding and James Shapiro. None of the Managing Members of KVA has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Read SEC document |
| September 13, 2016 Filed Sep 16, 2016 00:30 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 21,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-079954 · doc1.xml · nonDerivative · entry 1 Castelein Caley · CIK 0001355758 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,625 F1 · shares: Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon vesting. 100% of the RSUs shall be fully vested as of the date of grant, however, delivery of the shares will be deferred until the earlier of (i) the Reporting Person's termination of service from the Issuer's board of directors or (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.